



GLAND PHARMA LIMITED

February 18, 2026

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Changes among Senior Management Personnel

In compliance of the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; we would like to inform you that Dr. Jitendra Gangwal has been appointed as Vice-President (Research and Development), a Senior Management Personnel of the Company with effect from February 18, 2026.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are given in **Annexure-A** enclosed herewith.

This is for your information and records.

**Yours truly,
For Gland Pharma Limited**

**Sampath Kumar Pallerlamudi
Company Secretary & Compliance Officer**

Encl: As above

**Annexure A**

Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024

Details of Dr. Jitendra Gangwal

SI. No	Particulars	Remarks
1	Reason for change	Dr. Jitendra Gangwal has been appointed as Vice-President (Research & Development), a Senior Management Personnel of the Company with effect from February 18, 2026.
2	Date of Change	February 18, 2026
3	Brief profile	<p>Dr. Jitendra Gangwal is a pharmaceutical R&D leader with 24⁺ years of progressive experience across premier research institutions and leading Indian pharmaceutical organizations, demonstrating steady growth from scientific research roles to executive leadership in formulation R&D.</p> <p>Across his career, he has developed 55⁺ products spanning injections, ophthalmics, inhalation, nasal, and oral routes, filed 10⁺ patents, led multiple 505(b)(2) and ANDA filings, and established state-of-the-art R&D facilities. His expertise spans complex parenterals, nano-crystals, liposomes, microspheres, depot systems, peptides, metal complexes, and advanced polymer-based delivery systems.</p> <p>He combines deep scientific expertise with strategic business acumen, regulatory insight, and strong leadership capability to deliver high-value, commercially viable complex products in regulated global markets.</p> <p>Before joining Gland Pharma, Dr. Jitendra Gangwal is associated with National Chemical Laboratory (NCL); Pune, Dr. Reddy's Laboratories Limited, Glenmark Pharmaceuticals Limited, Alkem Laboratories Limited and FDC Limited.</p> <p>Dr. Gangwal holds a PhD from National Chemical Laboratory, Pune.</p>



4	Disclosure of relationships between director	Not Applicable
5	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/24, both dated June 20, 2018	Not Applicable